EF Hutton Acquisition Co. I upgraded shares of Enlivex Therapeutics (NASDAQ:ENLV – Free Report) to a strong-buy rating in a research report released on Tuesday, Zacks.com reports.
Separately, HC Wainwright decreased their target price on Enlivex Therapeutics from $7.00 to $6.00 and set a buy rating for the company in a report on Tuesday, June 11th.
Check Out Our Latest Stock Report on Enlivex Therapeutics
Enlivex Therapeutics Stock Performance
Enlivex Therapeutics (NASDAQ:ENLV – Get Free Report) last issued its earnings results on Friday, June 14th. The company reported ($0.22) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.25) by $0.03. Equities analysts forecast that Enlivex Therapeutics will post -0.81 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
An institutional investor recently bought a new position in Enlivex Therapeutics stock. XTX Topco Ltd purchased a new position in Enlivex Therapeutics Ltd. (NASDAQ:ENLV – Free Report) in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund purchased 24,820 shares of the company’s stock, valued at approximately $35,000. XTX Topco Ltd owned about 0.12% of Enlivex Therapeutics at the end of the most recent reporting period. 1.02% of the stock is currently owned by institutional investors.
About Enlivex Therapeutics
Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial.
Featured Stories
- Five stocks we like better than Enlivex Therapeutics
- Best of the list of Dividend Aristocrats: Build wealth with the aristocrat index
- The Solar Stock Battle: Is Daqo or JinkoSolar Your Next Big Win?
- How to Choose Top Rated Stocks
- Are These Chinese Stocks a Buy? Michael Burry’s Top Picks Say Yes
- What Are the U.K. Market Holidays? How to Invest and Trade
- Five Below Stock Faces Challenges Despite Strong Revenue Growth
Receive News & Ratings for Enlivex Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enlivex Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.